Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baricitinib for systemic lupus erythematosus - Authors' reply.
Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. Wallace DJ, et al. Among authors: de bono s. Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. Lancet. 2019. PMID: 30712893 No abstract available.
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS. Genovese MC, et al. Among authors: de bono s. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247. N Engl J Med. 2016. PMID: 27028914 Free article. Clinical Trial.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Taylor PC, et al. Among authors: de bono s. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. N Engl J Med. 2017. PMID: 28199814 Free article. Clinical Trial.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Wallace DJ, et al. Among authors: de bono s. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P. Tanaka Y, et al. Among authors: de bono s. Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22. Arthritis Rheumatol. 2018. PMID: 30058112 Free PMC article.
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC. Tanaka Y, et al. Among authors: de bono s. Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30. Ann Rheum Dis. 2019. PMID: 31040122 Free PMC article. Clinical Trial.
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW. Dörner T, et al. Among authors: de bono s. Lupus Sci Med. 2020 Oct;7(1):e000424. doi: 10.1136/lupus-2020-000424. Lupus Sci Med. 2020. PMID: 33037080 Free PMC article. Clinical Trial.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. Marconi VC, et al. Among authors: de bono s. Lancet Respir Med. 2021 Dec;9(12):1407-1418. doi: 10.1016/S2213-2600(21)00331-3. Epub 2021 Sep 1. Lancet Respir Med. 2021. PMID: 34480861 Free PMC article. Clinical Trial.
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC; COV-BARRIER Study Group. Ely EW, et al. Among authors: de bono s. Lancet Respir Med. 2022 Apr;10(4):327-336. doi: 10.1016/S2213-2600(22)00006-6. Epub 2022 Feb 3. Lancet Respir Med. 2022. PMID: 35123660 Free PMC article. Clinical Trial.
Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
Dörner T, van Vollenhoven RF, Doria A, Jia B, Ross Terres JA, Silk ME, de Bono S, Fischer P, Wallace DJ. Dörner T, et al. Among authors: de bono s. Arthritis Res Ther. 2022 May 16;24(1):112. doi: 10.1186/s13075-022-02794-x. Arthritis Res Ther. 2022. PMID: 35578304 Free PMC article. Clinical Trial.
50 results